Figure 3
IL-17RB enhances gemcitabine resistance via MUC1 and MUC4. (A) cell viability was measured by MTT assay in parental, scramble, and IL-17RB-knockdown BxPC3 cells treated with gemcitabine for 48 h. Statistical significance was calculated by comparison of shIL-17RB-1 or shIL-17RB-2 compared to Scramble. (B) The IC50 of gemcitabine toxicity was shown in mean ± SD. (C) Cell viability was measured by MTT assay in ectopic IL-17RB-overexpressed, MUC1-knockdown, MUC4-knockdown SU.86.86 cells. Statistical significance was calculated by comparison of IL-17RB OE with P. Ct., and OE/shMUC1 or OE/shMUC4 with OE/Scramble. The IC50 of gemcitabine toxicity was estimated in (D). Synergistic effect of MUC1 inhibitor Go-201 (5 μM) and gemcitabine (0.25 µM) on cell viability measured by MTT assay in BxPC3 and ectopic IL-17RB-overexpressing SU.86.86 cells (E). Asterisks (*, **, ***) indicated the statistical significance of P value less than 0.05, 0.01, or 0.001, respectively.
